OTLK, WDC Lead EPS Revision Winners: +42.7% and +33.1% Gains
OTLK surged 42.7% after its EPS growth estimate was revised to 53.0% and the FDA accepted its BLA resubmission for wet AMD. WDC climbed 33.1% on AI memory demand and a Mizuho price target hike. BIOA, ONTO, and BFLY also gained over 20% following upward EPS revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| OTLK | Healthcare | 2026-06-11 | +4.8pp | +42.7% |
| WDC | Technology | 2026-06-07 | +1.2pp | +33.1% |
| BIOA | Healthcare | 2026-06-07 | +1.2pp | +30.5% |
| ONTO | Technology | 2026-06-07 | +1.7pp | +24.8% |
| BFLY | Healthcare | 2026-06-07 | N/A | +23.6% |
Why did OTLK stock jump in June 2026?
OTLK jumped 42.7% (from $1.10 to $1.57) after analysts raised its forward EPS growth estimate from 48.3% to 53.0% on June 11.
The gain accelerated on June 16 when the FDA accepted the resubmitted Biologics License Application for ONS-5010/LYTENAVA as a treatment for wet AMD, setting a PDUFA goal date of July 29, 2026. The revision captured the inflection point in earnings expectations ahead of a potential approval, which would make ONS-5010 the first FDA-approved ophthalmic bevacizumab formulation.
OTLK EPS revision history → · Screener snapshot from 2026-06-11 →
FAQ: OTLK
Why did OTLK stock jump in June 2026?
OTLK jumped 42.7% from $1.10 to $1.57 after analysts raised its forward EPS growth estimate from 48.3% to 53.0% on June 11, followed by FDA acceptance of its BLA resubmission on June 16.
Is OTLK a buy after the rally?
The FDA's Class 1 review with a July 29 PDUFA date suggests a near-term catalyst, but the stock has already priced in some optimism. Investors should weigh the binary risk of approval vs. rejection.
What is OTLK's EPS growth estimate?
OTLK's forward EPS growth estimate was revised upward from 48.3% to 53.0% on June 11, reflecting improved expectations for profitability tied to the potential approval of LYTENAVA.
Why did WDC stock jump in June 2026?
WDC jumped 33.1% (from $511.72 to $681.08) after analysts raised its forward EPS growth estimate from 74.5% to 75.7% on June 7.
The revision was reinforced by a June 8 Mizuho price target hike to $685, citing AI-driven supply-demand imbalances in memory and storage. Additionally, a June 15 Iran peace deal rotated capital into economically sensitive names like Western Digital, further lifting the stock alongside memory peers Sandisk and Seagate.
WDC EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: WDC
Why did WDC stock jump in June 2026?
WDC jumped 33.1% from $511.72 to $681.08 after its EPS growth estimate was revised to 75.7% on June 7, bolstered by Mizuho's AI-driven price target hike and a broader rotation into tech on the Iran peace deal.
What caused WDC's surge?
The surge was caused by an upward EPS estimate revision, AI memory demand raising Mizuho's price target to $685, and a macro shift into cyclical stocks following the US-Iran Strait of Hormuz deal.
Is WDC a buy after the rally?
With a 33.1% gain and the stock now trading above Mizuho's $685 target, upside may be limited short-term. However, continued AI memory demand supports long-term growth for WDC as a NAND and HDD leader.
Why did BIOA stock jump in June 2026?
BIOA jumped 30.5% (from $15.70 to $20.49) after analysts raised its forward EPS growth estimate from 25.3% to 26.6% on June 7.
The move occurred without company-specific news, suggesting the revision itself caught the market's attention. BioAge Labs operates in the healthcare sector, where investor sentiment has been strong for biotech names with improving profitability outlooks and pipeline progress.
BIOA EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: BIOA
Why did BIOA stock jump in June 2026?
BIOA jumped 30.5% from $15.70 to $20.49 after analysts revised its forward EPS growth estimate from 25.3% to 26.6% on June 7, reflecting improved earnings expectations.
What is BIOA's EPS growth estimate?
BIOA's forward EPS growth estimate was revised upward to 26.6% on June 7, up from 25.3% previously.
Is BIOA a buy after the rally?
The 30.5% gain without confirming news suggests the market is pricing in the improved estimate. Investors should monitor upcoming clinical data or earnings reports for further validation.
Why did ONTO stock jump in June 2026?
ONTO jumped 24.8% (from $253.24 to $316.15) after analysts raised its forward EPS growth estimate from 30.4% to 32.1% on June 7.
The gain occurred without company-specific headlines, but Onto Innovation benefits from tailwinds in semiconductor inspection and metrology equipment, driven by AI chip demand and increased capital spending by foundries. The EPS revision signaled that analysts expect accelerating earnings growth.
ONTO EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: ONTO
Why did ONTO stock jump in June 2026?
ONTO jumped 24.8% from $253.24 to $316.15 after its forward EPS growth estimate was revised from 30.4% to 32.1% on June 7, reflecting stronger semiconductor equipment demand.
What caused ONTO's surge?
The surge was driven by an upward EPS revision and favorable sector trends in semiconductor equipment, supported by AI-led investments in advanced packaging and process control.
Is ONTO a buy after the rally?
The stock has gained 24.8% on the revision alone. With a forward P/E that may have expanded, investors should consider the sustainability of semiconductor spending before chasing the move.
Why did BFLY stock jump in June 2026?
BFLY jumped 23.6% (from $4.57 to $5.65) after its forward EPS growth estimate was revised to 26.8% on June 7.
No company news emerged during the window, indicating the revision captured an inflection point in profitability expectations. Butterfly Network's ultrasound technology is gaining traction in point-of-care applications, and the revised estimate suggests analysts see accelerating adoption and margin improvement ahead.
BFLY EPS revision history → · Screener snapshot from 2026-06-07 →
FAQ: BFLY
Why did BFLY stock jump in June 2026?
BFLY jumped 23.6% from $4.57 to $5.65 after analysts revised its forward EPS growth estimate to 26.8% on June 7, signaling improved profitability expectations.
What is BFLY's EPS growth estimate?
BFLY's forward EPS growth estimate was revised upward to 26.8% on June 7, indicating expected earnings acceleration.
What caused BFLY's surge?
The surge was caused solely by the upward EPS revision, as no company news accompanied the move. The estimate revision likely reflected growing confidence in Butterfly's expanding installed base and margin trajectory.
Today's top performers — OTLK, WDC, BIOA, ONTO, and BFLY — all gained over 20% following upward EPS estimate revisions. The trend highlights that earnings growth revisions, especially when paired with catalysts like FDA approvals or AI demand, remain a powerful driver of stock price momentum in both healthcare and technology sectors.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →